LONDON and MONTREAL, March 31, 2017 /PRNewswire/ -- DalCor Pharmaceuticals today announced
The Company's presentation will be webcast live on the company's corporate website at www.dalcorpharma.com. To access the live webcast please log onto the DalCor website approximately fifteen minutes before the presentation to register and download any necessary audio software. The audio presentation will be available at this link: http://wsw.com/webcast/needham80/dalc for a limited time after the live presentation.
About DalCor Pharmaceuticals DalCor is developing precision treatments by genetically targeting patients that will derive clinical benefits. By integrating clinical and genetic insights, DalCor intends to deliver superior clinical cardiovascular outcomes. The company's first development program, dalcetrapib, is intended to reduce cardiovascular events in a specific genetic subset of patients.
On March 7, DalCor announced it is ahead of its enrollment schedule with the randomization of over 1,000 patients of the expected 5,000 patients planned for the Phase 3 "dal-GenE" clinical trial, a cardiovascular outcomes study of dalcetrapib in patients with acute coronary syndrome (ACS) and the AA genotype in the ADCY9 gene. Patients have been recruited at 642 hospitals in 30 countries, including the U.S., and on six continents.
DalCor has a worldwide exclusive license for dalcetrapib together with rights to the genetic marker for use with dalcetrapib and is sponsoring the dal-GenE study.
DalCor Pharmaceuticals has offices in Montreal, San Mateo, Calif., Zug, Switzerland and Stockport, U.K. For more information, visit www.dalcorpharma.com
DalCor Contacts: Russo Partners Alexander Fudukidis (646) 942-5632 [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/dalcor-pharmaceuticals-to-present-at-needham--co-healthcare-conference-300432678.html
SOURCE DalCor Pharmaceuticals
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All